Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 10/2001

01-08-2001 | Review Article

Oral Contraceptives and Cancer

An Update

Authors: Dr Carlo La Vecchia, Andrea Altieri, Silvia Franceschi, Alessandra Tavani

Published in: Drug Safety | Issue 10/2001

Login to get access

Abstract

Most up-to-date information on oral contraceptives (OCs) and breast cancer risk comes from a collaborative re-analysis of individual data on 53 297 cases and 100 239 controls. It is now established that there is a moderately increased breast cancer risk among current OC users, which tends to level off in the few years after stopping use. With regard to cervical cancer, OC use has been found to be associated with increased risk in human papilloma virus—positive women. With reference to the well known protective effects of OCs against endometrial carcinogenesis, additional information has suggested a consistent protection across types of OCs used. Further data on ovarian cancer confirm that the protection of OCs is long lasting, and may well be observed 15 to 20 years after stopping use. Several studies have suggested an inverse relationship between use of OCs and risk of colorectal cancer, and in a meta-analysis of published data the pooled relative risk of colorectal cancer for OC ever-use was 0.82 (95% confidence interval 0.74 to 0.97). There was no association with duration of use. The increased risk for hepatocellular carcinoma in the absence of hepatitis B viruses is the only established evidence of a direct association between OC use and cancer risk, which led an International Agency for Research on Cancer Working Group to classify OCs as carcinogenic to humans in 1998.
Literature
1.
Beral V, Hermon C, Kay C, et al. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46000 women from Royal College of General Practitioners’ oral contraception study. BMJ 1999; 318: 96–100PubMed
2.
Chaouki N, Bosch FX, Munoz N, et al. The viral origin of cervical cancer in Rabat, Morocco. Int J Cancer 1998; 75: 546–54PubMed
3.
Moreno V, Bosch FX, Munoz N, et al. The risk of cervical cancer in relation to hormonal contraceptives in women that are HPV-DNA carriers. Pooled analysis of the IARC multicentric case-control study [abstract 61]. Proceedings of the 18th International Papillomavirus Conference; 2000 Jul 25; Barcelona. 23–28, 129
4.
Lacey Jr JV, Brinton LA, Abbas FM, et al. Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 1999; 8: 1079–85PubMed
5.
Thomas DB, Ray RM, The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Oral contraceptives and invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. Am J Epidemiol 1996; 144: 281–9PubMed
6.
Parazzini F, Chatenoud L, La Vecchia C, et al. Time since last use of oral contraceptives and risk of invasive cervical cancer. Eur J Cancer 1998; 34: 884–8PubMed
7.
Fernandez E, La Vecchia C, Franceschi S, et al. Oral contraceptive use and risk of colorectal cancer. Epidemiology 1998; 9: 295–300PubMed
8.
Fernandez E, Bosetti C, La Vecchia C, et al. Sex differences in colorectal cancer mortality in Europe, 1955-1966. Eur J Cancer Prev 2000; 9; 99–104PubMed
9.
Beard CM, Hartmann LC, Atkinson EJ, et al. The epidemiology of ovarian cancer: A population-based study in Olmsted County, Minnesota, 1935-1991. Ann Epidemiol 2000; 10: 14–23PubMed
10.
Ness RB, Grisso JA, Klapper J, et al. And the SHARE Study Group. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. Am J Epidemiol 2000; 152: 233–4PubMed
11.
Greggi S, Parazzini F, Paratore MP, et al. Risk factors for ovarian cancer in central Italy. Gynecol Oncol 2000; 79: 50–4PubMed
12.
Narod DA, Risch H, Moslehi R, et al. For the Hereditary Ovarian Cancer Clinical Study Group. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 1998; 339: 424–8PubMed
13.
Chiaffarino F, Pelucchi C, Parazzini F, et al. Reproductive and hormonal factors and ovarian cancer. Ann Oncol 2001; 12: 337–41PubMed
14.
Weiderpass E, Adami H-O, Baron JA, et al. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 1999; 10: 277–84PubMed
15.
McCann SE, Freudenheim JL, Marshall JR, et al. Diet in the epidemiology of endometrial cancer in Western New York (United States). Cancer Causes Control 2000; 11: 965–74PubMed
16.
Collaborative MILTS Project Team. Oral contraceptives and liver cancer. Contraception 1997; 56: 275–84
17.
La Vecchia C, Ron E, Franceschi S, et al. A pooled analysis of case-control studies of thyroid cancer. III: oral contraceptives, menopausal replacement therapy and other female hormones. Cancer Causes Control 1999; 10: 157–66PubMed
18.
International Agency for Research on Cancer. Monographs on the evaluation of the carcinogenic risks to humans. Vol. 72. Hormonal contraception and post-menopausal hormonal therapy. Lyon: International Agency for Research on Cancer, 1999
19.
La Vecchia C, Tavani A, Franceschi S, et al. Oral contraceptives and cancer: a review of the evidence. Drug Saf 1996; 14: 260–72PubMed
20.
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713–27
21.
Grabrick DM, Hartmann LC, Cerhan JR, et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA 2000; 284: 1791–8PubMed
22.
Lipworth L, Katsouyanni K, Stuver S, et al. Oral contraceptives, menopausal estrogens, and the risk of breast cancer: a case-control study in Greece. Int J Cancer 1995; 62: 548–51PubMed
23.
Levi F, Lucchini F, La Vecchia C. Oral contraceptives, menopausal hormone replacement treatment and breast cancer risk. Eur J Cancer Prev 1996; 5: 259–66PubMed
24.
Newcomb PA, Longnecker MP, Storer BE, et al. Recent oral contraceptive use and risk of breast cancer (United States). Cancer Causes Control 1996; 7: 525–32PubMed
25.
Tryggvadottir L, Tulinius H, Gudmundsdotttir GB. Oral contraceptive use at a young age and the risk of breast cancer: an Icelandic, population-based cohort study of the effect of birth year. Br J Cancer 1997; 75 139–43PubMed
26.
Magnusson CM, Persson IR, Baron JA, et al. The role of reproductive factors and use of oral contraceptives in the aetiology of breast cancer in women age 50 to 74 years. Int J Cancer 1999; 80: 231–6PubMed
27.
Ursin G, Wu AH, Hoover RN, et al. Breast cancer and oral contraceptive use in Asian-American women. Am J Epidemiol 1999; 150: 561–7PubMed
28.
Van Hoften C, Burger H, Peeters PHM, et al. Long-term oral contraceptive use increases breast cancer risk in women over 55 years of age: the DOM cohort. Int J Cancer 2000; 87: 591–4PubMed
29.
Shapiro S, Rosenberg L, Hoffman M, et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol 2000; 151: 396–403PubMed
30.
International Agency for Research on Cancer. Monographs on the evaluation of the carcinogenic risks to humans. Vol. 64. Human papillomaviruses. Lyon: International Agency for Research on Cancer, 1995
31.
Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12–9PubMed
32.
Daling JR, Madeleine MM, McKnight B, et al. The relationship of human papillomavirus-related cervical tumors to cigarette smoking, oral contraceptive use, and prior herpes simplex virus type 2 infection. Cancer Epidemiol Biomarkers Prev 1996; 5: 541–8PubMed
33.
Ngelangel C, Munoz N, Bosch FX, et al. Causes of cervical cancer in the Philippines: a case-control study. J Natl Cancer Inst 1998; 90: 43–9PubMed
34.
Chichareon S, Herrero R, Munoz N, et al. Risk factors for cervical cancer in Thailand: a case-control study. J Natl Cancer Inst 1998; 90: 50–7PubMed
35.
Deacon JM, Evans CD, Yule R, et al. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer 2000; 88: 1565–72
36.
Vizcaino AP, Moreno V, Bosch FX, et al. International trends in the incidence of cervical cancer: I, adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer 1998; 75: 536–45PubMed
37.
La Vecchia C. The long-term impact of oral contraceptives on ovarian and endometrial carcinogenesis. Eur J Cancer Prev 2000; 9: 137–8PubMed
38.
CASH (Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute ofChild Health and Human Development). Combination oral contraceptive use and the risk of endometrial cancer. JAMA 1987; 257: 796–800
39.
Voigt LF, Deng Q, Weiss NS. Recency, duration and progestin content or oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA). Cancer Causes Control 1994; 5: 227–33PubMed
40.
Levi F, La Vecchia C, Gulie C, et al. Oral contraceptives and the risk of endometrial cancer. Cancer Causes Control 1991; 2: 99–103PubMed
41.
Parslov M, Lidegaard 0, Klintorp S, et al. Risk factors among young women with endometrial cancer: a Danish case-control study. Am J Obstet Gynecol 2000; 182: 23–9PubMed
42.
Parazzini F, Franceschi S, La Vecchia C, et al. The epidemiology of ovarian cancer. Gynecol Oncol 1991; 43: 9–23PubMed
43.
La Vecchia C, Lucchini F, Negri E, et al. Trends of cancer mortality in Europe, 1955-1989. III: breast and genital sites. Eur J Cancer 1992; 28A: 927–98PubMed
44.
La Vecchia C, Negri E, Levi F, et al. Cancer mortality in Europe: effects of age, cohort of birth and period of death. Eur J Cancer 1998; 34: 118–41PubMed
45.
La Vecchia C, Franceschi S. Oral contraceptives and ovarian cancer. Eur J Cancer Prev 1999; 8: 297–304PubMed
46.
Levi F, Gutzwiller F, Decarli A, et al. Oral contraceptive use and breast and ovarian cancer mortality in Switzerland. J Epidemiol Comm Health 1987; 41: 267–8
47.
Villard-Mackintosh L, Vessey MP, Jones L. The effects of oral contraceptives and parity on ovarian cancer trends in women under 55 years of age. Br J Obstet Gynecol 1989; 96: 783–8
48.
Adami H-O, Hsieh C-C, Lambe M, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet 1994; 334: 1250–4
49.
dos Santos Silva I, Swerdlow AJ. Recent trends in incidence of and mortality from breast, ovarian and endometrial cancers in England and Wales and their relation to changing fertility and oral contraceptive use. Br J Cancer 1995; 72: 485–92PubMed
50.
Koper NP, Kiemeney LALM, Massuger LFAG, et al. Ovarian cancer incidence (1989-1991) and mortality (1954-1993) in the Netherlands. Obstet Gynecol 1996; 88: 387–93PubMed
51.
Levi F, Lucchini F, Negri E, et al. Cancer mortality in Europe, 1990-94, and an overview of trends from 1955 to 1994. Eur J Cancer 1999; 35: 1477–516PubMed
52.
Tarone RE, Chu KC. Age-period-cohort analyses of breast-, ovarian, endometrial- and cervical-cancer mortality rates for Caucasian women in the USA. J Epidemiol Biostat 2000; 5: 221–31PubMed
53.
Ramcharan S, Pellegrin FA, Ray R, et al. The Walnut Creek Contraceptive Study: a prospective study of the side effects of oral contraceptives. Bethesda (MD): National Institute of Health, 1981: NIH publication no. 81–564, Vol. III
54.
Vessey MP, Painter R. Endometrial and ovarian cancer and oral contraceptives: findings in a large cohort study. Br J Cancer 1995; 71: 1340–2PubMed
55.
Hankinson SE, Colditz GA, Hunter DJ, et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 1995; 76: 284–90PubMed
56.
Beral V, Hannaford P, Kay C. Oral contraceptive use and malignancies of the genital tract: results of the Royal College of General Practitioners’ Oral Contraception Study. Lancet 1988; I: 1331–5
57.
Willett WC, Bain C, Hennekens CH, et al. Oral contraceptives and risk of ovarian cancer. Cancer 1981; 48: 1684–7PubMed
58.
Hildreth NG, Kelsey JL, LiVolsi VA, et al. An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol 1981; 114: 398–405PubMed
59.
Weiss NS, Lyon JL, Liff JM, et al. Incidence of ovarian cancer in relation to the use of oral contraceptives. Int J Cancer 1981; 28: 669–71PubMed
60.
Cramer DW, Hutchison GB, Welch WR, et al. Factors affecting the association of oral contraceptives and ovarian cancer. N Engl J Med 1982; 307: 1047–51PubMed
61.
Rosenberg L, Palmer JR, Zauber AG, et al. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 1994; 139: 654–61PubMed
62.
Risch HA, Weiss NS, Lyon JL, et al. Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol 1983; 117: 128–39PubMed
63.
Tzonou A, Day NE, Trichopoulos D, et al. The epidemiology of ovarian cancer in Greece: a case-control study. Eur J Cancer Clin Oncol 1984; 20: 1045–52PubMed
64.
Harlow BL, Weiss NS, Roth GJ, et al. Case-control study of borderline ovarian tumors: reproductive history and exposure to exogenous female hormones. Cancer Res 1988; 48: 5849–52PubMed
65.
Wu ML, Whittemore AS, Paffenbarger Jr RS, et al. Personal and environmental characteristics related to epithelial ovarian cancer. I: reproductive and menstrual events and oral contraceptive use. Am J Epidemiol 1988; 128: 1216–27PubMed
66.
Shu XO, Brinton LA, Gao YT, et al. Population-based case-control study of ovarian cancer in Shangai. Cancer Res 1989; 49: 3670–4PubMed
67.
World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Epithelial ovarian cancer and combined oral contraceptives. Int J Epidemiol 1989; 18: 538–45
68.
Hartge P, Schiffman MH, Hoover R, et al. A case-control study of epithelial ovarian cancer. Am J Obstet Gynecol 1989; 161: 10–6PubMed
69.
Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case-control study. Br J Cancer 1989; 60: 592–8PubMed
70.
Parazzini F, La Vecchia C, Negri E, et al. Oral contraceptives use and the risk of ovarian cancer: an Italian case-control study. Eur J Cancer 1991; 27: 594–8PubMed
71.
Parazzini F, Restelli C, La Vecchia C, et al. Risk factors for epithelial ovarian tumours of borderline malignancy. Int J Epidemiol 1991; 20: 871–7PubMed
72.
Polychronopoulou A, Tzonou A, Hsieh C, et al. Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer. Int J Cancer 1993; 55: 402–7PubMed
73.
Rosenberg L, Shapiro S, Slone D, et al. Epithelial ovarian cancer and combination oral contraceptives. JAMA 1982; 247: 3210–2PubMed
74.
Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 1994; 140: 585–97PubMed
75.
Risch HA, Marrett LD, Jain M, et al. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 1996; 144: 363–72PubMed
76.
Purdie D, Green A, Bain C, et al. For the Survey of Women’s Health Group. Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Int J Cancer 1995; 62: 678–84PubMed
77.
Franceschi S, Parazzini F, Negri E, et al. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer. III: oral contraceptive use. Int J Cancer 1991; 49: 61–5PubMed
78.
Whittemore AS, Harris R, Intyre J, the Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II: invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992; 136: 1184–203PubMed
79.
John EM, Whittemore AS, Harris R, et al., and the Collaborative Ovarian Cancer Group Characteristics relating to ovarian cancer risk: collaborative analysis of seven U.S. case-control studies. Epithelial ovarian cancer in black women. J Natl Cancer Inst 1993; 85: 142–7PubMed
80.
Harris R, Whittemore AS, Intyre J, and the Collaborative Ovarian Cancer Group. (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12US case-control studies. III: epithelial tumors of low malignant potential in white women. Am J Epidemiol 1992; 136: 1204–11PubMed
81.
Fioretti F, La Vecchia C, Tavani A, et al. Package inserts of oral contraceptives in Italy. Pharmacoepidemiol Drug Saf 1996; 5: 315–9PubMed
82.
Horn-Ross PL, Whittemore AS, Harris R, et al., and the Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative Analysis of 12 U.S. case-control Studies. VI: nonepithelial cancers among adults. Epidemiology 1992; 3: 490–5PubMed
83.
Parazzini F, La Vecchia C, Franceschi S, et al. Risk factors for endometrioid, mucinous and serous benign ovarian cysts. Int J Cancer 1989; 18: 108–12
84.
Booth M, Beral V, Maconochie N, et al. Acase-control study of benign ovarian tumours. J Epidemiol Community Health 1992; 46: 528–31PubMed
85.
Westhoff C, Pike M, Vessey M. Benign ovarian teratomas: a population-based case-control study. Br J Cancer 1988; 58: 93–8PubMed
86.
Parazzini F, La Vecchia C, Negri E, et al. Risk factors for benign ovarian teratomas. Br J Cancer 1995; 71: 644–6PubMed
87.
Rosenblatt KA, Thomas DB, Noonan EA, the WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Highdose and low-dose combined oral contraceptives: protection against epithelial ovarian cancer and the length of the protective effect. Eur J Cancer 1992; 28A: 1872–6PubMed
88.
Jernstrom H, Chu W, Vesprini D, et al. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. Mol Genet Metab 2001; 72: 144–54PubMed
89.
Simon WE, Albrecht M, Hänsel M, et al. Cell lines derived from human ovarian carcinomas: growth stimulation by gonadotropic and steroid hormones. J Natl Cancer Inst 1983; 70: 839–45PubMed
90.
Negri E, Tzonou A, Beral V, et al. Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies. Int J Cancer 1999; 80: 848–51PubMed
91.
Gross TP, Schlesselman JJ. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol 1994; 83: 419–24PubMed
92.
Fraumeni JF, Lloyd JW, Smith EM, et al. Cancer mortality among nuns: role of marital status in etiology of neoplastic disease in women. J Natl Cancer Inst 1969; 42: 455–68PubMed
93.
Herbert-Croteau N. A meta-analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiol Biomarkers Prev 1998; 7: 653–9
94.
Fernandez E, La Vecchia C, Balducci A, et al. Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cancer; 2001; 84: 722–7PubMed
95.
Weiss NS, Daling JR, Chow WH. Incidence of cancer of the large bowel in women in relation to reproductive and hormonal factors. J Natl Cancer Inst 1981; 67: 57–60PubMed
96.
Potter JD, McMichael AJ. Large bowel cancer in women in relation to reproductive and hormonal factors: a case-control study. J Natl Cancer Inst 1983; 71: 703–9PubMed
97.
Furner SE, Davis FG, Nelson RL, et al. A case-control study of large bowel cancer and hormone exposure in women. Cancer Res 1989; 49: 4936–40PubMed
98.
Kune GA, Kune S, Watson LF. Oral contraceptive use does not protect against large bowel cancer. Contraception 1990; 41: 19–25PubMed
99.
Wu-Williams AH, Lee M, Wittemore AS, et al. Reproductive factors and colorectal cancer risk among Chinese females. Cancer Res 1991; 51: 2307–11PubMed
100.
Fernandez E, La Vecchia C, D’Avanzo B, et al. Oral contraceptives, hormone replacement therapy and the risk of colorectal cancer. Br J Cancer 1996; 73: 1431–5PubMed
101.
Talamini R, Franceschi S, Dal Maso L, et al. The influence of reproductive and hormonal factors on the risk of colon and rectal cancer in women. Eur J Cancer 1998; 34: 1070–6PubMed
102.
Martinez ME, Grodstein F, Giovannucci E, et al. A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 1997; 6: 1–5PubMed
103.
Troisi R, Schairer C, Chow W-H, et al. Reproductive factors, oral contraceptive use, a risk of colorectal cancer. Epidemiology 1997; 8: 75–9PubMed
104.
van Wayenburg CAM, van der Schouw YT, van Noord PAH. Age at menopause, body mass index, and the risk of colorectal cancer mortality in the Dutch Diagnostisch Onderzoeck Mammacarcinoom (DOM) cohort. Epidemiology 2000; 11: 304–8PubMed
105.
McMichael AJ, Potter J. Host factors in carcinogenesis: certain bile-acid metabolis profiles that selectively increase the risk of proximal colon cancer. J Natl Cancer Inst 1985; 75: 185–91PubMed
106.
Lointier P, Wildrick DM, Boman BM. The effects of steroid hormones on a human colon cancer cell line in vitro. Anticancer Res 1992; 12: 1327–30PubMed
107.
Thomas ML, Xu X, Norfleet AM, et al. The presence of functional estrogen receptors in intestinal epithelial cells. Endocrinology 1993; 132: 426–30PubMed
108.
Issa JP, Ottaviano YL, Celano P, et al. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994; 7: 536–40PubMed
109.
Campagnoli C, Biglia N, Cantamessa C, et al. Insulin-like growth factor I (IGF-I) serum level modifications during transdermal estradiol treatment in postmenopausal women: a possible bimodal effect depending on basal IGF-I values. Gynecol Endocrinol 1998; 12: 259–66PubMed
110.
El Atiq F, Garrouste F, Remacle-Bonnet M, et al. Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer 1994; 57: 491–7PubMed
111.
Giovannucci E, Pollak MN, Platz EA, et al. Aprospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 2000; 9: 345–9PubMed
112.
Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst 1999; 91: 916–32PubMed
113.
La Vecchia C. Oral contraceptives, cancer and vascular disease. Eur J Cancer Prev. In press
Metadata
Title
Oral Contraceptives and Cancer
An Update
Authors
Dr Carlo La Vecchia
Andrea Altieri
Silvia Franceschi
Alessandra Tavani
Publication date
01-08-2001
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 10/2001
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200124100-00003

Other articles of this Issue 10/2001

Drug Safety 10/2001 Go to the issue

Review Article

Antihypertensive Therapy and Cancer Risk

Original Research Article

Postdischarge Adverse Drug Reactions in Primary Care Originating from Hospital Care in France

Practical Drug Safety

Prevention and Management of Antineoplastic-Induced Hypersensitivity Reactions

Review Article

Calcineurin Inhibitors and Post-Transplant Hyperlipidaemias

Leading Article

Clinical-Pharmacological Strategies to Assess Drug Interaction Potential During Drug Development